CD274 and non-small cell lung carcinoma: In addition to Nicolazzo et al., Guibert and colleagues [19] detected PD-L1+ CTCs in 93% of advanced NSCLC patients before Nivolumab treatment, with a median proportion of CTCs expressing PD-L1 of 17.2% using the ISET technology followed by immunostaining.